Article in Neurology. Clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Jennifer L PurksDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-4334-8253
Lakshmi ArbattiDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-9219-1961
Abhishek HosamathDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-8243-0682
Amy W AmaraDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-0762-9656
Karen E AndersonDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-2084-6869
Lana ChahineDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-2521-7196
Shirley W EberlyDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0009-0005-2338-2499
Daniel KinelDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-3082-230X
Sneha MantriDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-4556-0522
Soania MathurDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-6224-7573
David OakesDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-9154-6054
David G StandaertDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-2921-8348
Daniel WeintraubDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-0633-7168
Ira ShoulsonDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0001-6140-1797
Connie MarrasDepartment of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-9236-9328
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Background and Objectives: Cognitive impairment is experienced by up to 80% of people with Parkinson disease (PD). Little is known regarding the subjective experience and frequency of bothersome cognitive problems across the range of disease duration as expressed directly in patients' own words. We describe the types and frequency of bothersome cognitive symptoms reported verbatim by patients with PD. Methods: Through the online Fox Insight study and the Parkinson Disease Patient Report of Problems, we asked patients with PD to self-report by keyboard entry up to five most bothersome problems and how these problems affect their functioning. Human-in-the-loop curation, natural language processing, and machine learning were used to categorize responses into 8 cognitive symptoms: memory, concentration/attention, cognitive slowing, language/word finding, mental alertness/awareness, visuospatial abilities, executive abilities/working memory, and cognitive impairment not otherwise specified. Associations between cognitive symptoms and demographic and disease-related variables were examined in our cross-sectional cohort using multivariate logistic regression. Results: Among 25,192 participants (55% men) of median age 67 years and 3 years since diagnosis (YSD), 8,001 (32%) reported a cognitive symptom at baseline. The 3 most frequently reported symptoms were memory (13%), language/word finding (12%), and concentration/attention (9%). Depression was significantly associated with bothersome cognitive problems in all domains except visuospatial abilities. Predictors of reporting any cognitive symptom in PD were depression (adjusted OR 1.5), increasing MDS-UPDRS Part II score (OR 1.4 per 10-point increment), higher education (OR 1.2 per year), and YSD 1, 2, 6-7, and 8-9 vs 0 YSD. Among individuals with at least one cognitive symptom, posterior cortical-related cognitive symptoms (i.e., visuospatial, memory, and language) were reported by 17% (n = 4325), frontostriatal-related symptoms (i.e., executive abilities, concentration/attention) by 7% (n = 1,827), and both by 14.2% (n = 1,020). Odds of reporting posterior cortical symptoms vs frontostriatal symptoms increased with age and MDS-UPDRS part II score, but not depression. Discussion: Nearly one-third of participants with PD, even early in the disease course, report cognitive symptoms as among their most bothersome problems. Online verbatim reporting analyzed by human-in-the-loop curation, natural language processing, and machine learning is feasible on a large scale and allows a detailed examination of the nature and distribution of cognitive symptoms in PD.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cognitive Symptoms in Cross-Sectional Parkinson Disease Cohort Evaluated by Human-in-the-Loop Machine Learning and Natural Language Processing. · full record | OpenQuestion